GLPwatch
Papers (10646)
Page 21 of 178, ranked by citation count.
- A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
- Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome.
- Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
- Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.
- Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series.
- Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
- Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
- Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors.
- Diabesity: therapeutic options.
- Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
- Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
- Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.
- Proteomic changes upon treatment with semaglutide in individuals with obesity.
- Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.
- Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study.
- Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.
- Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.
- Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat.
- Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.
- Injectable and Thermosensitive Hydrogel Containing Liraglutide as a Long-Acting Antidiabetic System.
- Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.
- Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.
- Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding.
- Semaglutide and cancer: A systematic review and meta-analysis.
- Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases.
- Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.
- Psychological and quality of life changes in patients using GLP-1 analogues.
- Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
- Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
- Glucagon-like peptide-1 receptor agonist use in pregnancy: a review.
- Glucagon and heart in type 2 diabetes: new perspectives.
- Weight beneficial treatments for type 2 diabetes.
- The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
- Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3β Pathways.
- Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
- Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
- Exendin-4 Protects Against Myocardial Ischemia-Reperfusion Injury by Upregulation of SIRT1 and SIRT3 and Activation of AMPK.
- Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides.
- Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
- Exendin-4 improves β-cell function in autophagy-deficient β-cells.
- Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.
- Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats.
- Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.
- The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.
- Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner.
- The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease.
- Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors.
- Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial.
- Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
- Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway.
- Emerging pharmacotherapies for obesity: A systematic review.
- Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence.
- Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
- Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection.
- Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea.
- Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
- Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor.
- Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.
- GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
- The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.